J&J's TECVAYLI Wins FDA Approval in Earlier-Line Myeloma – BCMA BiTE Plus Daratumumab Combo Expands Addressable Market
CompanyDrug

J&J’s TECVAYLI Wins FDA Approval in Earlier-Line Myeloma – BCMA BiTE Plus Daratumumab Combo Expands Addressable Market

CompanyDrug

Fosun Pharma’s HLX97 Wins NMPA Phase I Approval – First-in-Class KAT6A/B Inhibitor Targets Advanced Solid Tumors

Insilico Medicine's AI-Driven ISM4808 Hits Phase I Milestone – TaiGen Doses First Subject in CKD Anemia Trial
CompanyDrug

Insilico Medicine’s AI-Driven ISM4808 Hits Phase I Milestone – TaiGen Doses First Subject in CKD Anemia Trial

Boan Biotech Partners with DP Technology on AI4S Drug Discovery – Antibody, ADC, and TCE Pipeline Acceleration
CompanyDeals

Boan Biotech Partners with DP Technology on AI4S Drug Discovery – Antibody, ADC, and TCE Pipeline Acceleration

HutchMed Reports $548.5 Million 2025 Revenue – FRUZAQLA Drives 26% Growth Amid China Market Headwinds
Company

HutchMed Reports $548.5 Million 2025 Revenue – FRUZAQLA Drives 26% Growth Amid China Market Headwinds

CompanyDrug

HutchMed Initiates Phase I/IIa Trial for HMPL-A580 – Second Antibody-Targeted Triggered Conjugate Targets EGFR+ Solid Tumors

AbbVie's SKYRIZI Hits AFFIRM Study Endpoints in Crohn's Disease – 55% Clinical Remission vs. 30% Placebo at Week 12
CompanyDrug

AbbVie’s SKYRIZI Hits AFFIRM Study Endpoints in Crohn’s Disease – 55% Clinical Remission vs. 30% Placebo at Week 12

China's 2026 Government Work Report Unveils Healthcare Overhaul – VBP Optimization, TCM Innovation, and 300M Long‑Term Care Expansion
Policy / Regulatory

China’s 2026 Government Work Report Unveils Healthcare Overhaul – VBP Optimization, TCM Innovation, and 300M Long‑Term Care Expansion

CompanyDeals

AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics

CompanyDrug

Ab&B Bio-Tech Wins FDA IND Approval for mRNA Mpox Vaccine – China’s First U.S.-Cleared Candidate Targets Immunocompromised Populations

Novo Nordisk's CagriSema Fails Non‑Inferiority Test Against Lilly's Zepbound in Phase III REDEFINE 4 Trial – 23% vs. 25.5% Weight Loss
CompanyDrug

Novo Nordisk’s CagriSema Fails Non‑Inferiority Test Against Lilly’s Zepbound in Phase III REDEFINE 4 Trial – 23% vs. 25.5% Weight Loss

Bayer Reports EUR 45.6 Billion 2025 Sales – Nubeqa and Kerendia Drive Pharma Growth Amid Xarelto Patent Cliff
Company

Bayer Reports EUR 45.6 Billion 2025 Sales – Nubeqa and Kerendia Drive Pharma Growth Amid Xarelto Patent Cliff